- Home
- GLPG vs UNFI Comparison
GLPG vs UNFI Comparison
Compare GLPG & UNFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLPG
- UNFI
- Stock Information
- Founded
- GLPG 1999
- UNFI 1976
- Country
- GLPG Belgium
- UNFI United States
- Employees
- GLPG N/A
- UNFI N/A
- Industry
- GLPG Biotechnology: Pharmaceutical Preparations
- UNFI Food Distributors
- Sector
- GLPG Health Care
- UNFI Consumer Discretionary
- Exchange
- GLPG Nasdaq
- UNFI Nasdaq
- Market Cap
- GLPG 2.1B
- UNFI 2.2B
- IPO Year
- GLPG 2005
- UNFI 1996
- Fundamental
- Price
- GLPG $30.42
- UNFI $35.54
- Analyst Decision
- GLPG Hold
- UNFI Hold
- Analyst Count
- GLPG 4
- UNFI 9
- Target Price
- GLPG $31.33
- UNFI $37.25
- AVG Volume (30 Days)
- GLPG 169.3K
- UNFI 764.4K
- Earning Date
- GLPG 11-05-2025
- UNFI 12-02-2025
- Dividend Yield
- GLPG N/A
- UNFI N/A
- EPS Growth
- GLPG N/A
- UNFI N/A
- EPS
- GLPG N/A
- UNFI N/A
- Revenue
- GLPG $336,643,201.00
- UNFI $31,784,000,000.00
- Revenue This Year
- GLPG $1.77
- UNFI $2.54
- Revenue Next Year
- GLPG $0.44
- UNFI $1.94
- P/E Ratio
- GLPG N/A
- UNFI N/A
- Revenue Growth
- GLPG 10.31
- UNFI 2.60
- 52 Week Low
- GLPG $22.36
- UNFI $20.78
- 52 Week High
- GLPG $37.78
- UNFI $43.29
- Technical
- Relative Strength Index (RSI)
- GLPG 41.14
- UNFI 37.88
- Support Level
- GLPG $30.17
- UNFI $34.26
- Resistance Level
- GLPG $33.12
- UNFI $40.49
- Average True Range (ATR)
- GLPG 0.75
- UNFI 1.44
- MACD
- GLPG -0.04
- UNFI -0.52
- Stochastic Oscillator
- GLPG 22.55
- UNFI 18.01
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
About UNFI United Natural Foods Inc.
United Natural Foods Inc is a wholesale distributor of natural, organic and specialty foods and nonfood products across North America. The company's products consist of national, regional and private label brands grouped into grocery and general merchandise, produce, perishables and frozen foods, nutritional supplements and sports nutrition, bulk and foodservice products, and personal care items. United Natural Foods serves various retail formats including conventional supermarket chains, natural product superstores, independent retail operators and foodservice channels such as e-commerce platforms. The company's operations are comprised of principal divisions: the wholesale division; the retail division; and other.